Decision Support Tool for People with Advanced Breast Cancer
Official title: Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)
Run by Weill Medical College of Cornell University · NCT07635147 · Data updated 2026-11-12
This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 3 sites (Brooklyn, New York and 2 other locations) |
| Status | Recruiting |
| Started | June 17, 2026 |
| Main results expected | September 2027 |
| Study ends | February 2028 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07635147 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with stage IV/metastatic breast cancer who speak English, Spanish, or Mandarin are eligible.
✕Probably not a fit
Patients who do not experience changes in communication or who face barriers unrelated to the tool (e.g., rapidly changing illness) may not see a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study examines whether the COAST decision support tool can improve communication between patients with metastatic breast cancer and their oncology providers. Participants will complete surveys before using COAST and again 2–4 weeks later, with a subset invited to participate in interviews. The study takes place at NYP-Weill Cornell, NYP-Brooklyn Methodist, and NYP-Queens, and includes English, Spanish, and Mandarin speakers. The goal is to determine if COAST is acceptable and easy to use in a real-world clinical setting and whether it enhances shared decision-making about treatment options.
Why it matters
Potential benefit: If successful, COAST could help patients communicate their preferences more clearly and support more patient-centered treatment decisions.
How similar studies have gone: Past work on decision-support tools in cancer care has shown potential to improve communication and decision-making, though results vary by setting and tool.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female 18 years and older * Diagnosis of Stage IV breast cancer * English, Spanish or Mandarin speaking Exclusion Criteria: * Early breast cancer * Individuals speaking languages other than English, Spanish, or Mandarin as their primary language
Where it's running
-
NewYork-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, United States Recruiting -
NewYork-Presbyterian Medical Group Queens
Flushing, New York, United States Recruiting -
NewYork-Presbyterian David H. Koch Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Shoshana Rosenberg, ScD, MPH — Weill Medical College of Cornell University
- Study coordinator: Zori K Hamilton, MA
- Email: zkh4001@med.cornell.edu
- Phone: 646-962-3694
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exploring HER3-DXd treatment for advanced breast cancer
This study is testing a new treatment called HER3-DXd, both alone and with another drug, to see if it can help people with advanced breast cancer that hasn't responded to previous treatments.
-
Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors
This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.
-
T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer
This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.
-
Timing ctDNA Testing to Guide Treatment in Advanced Breast Cancer
This study tests how ctDNA levels and key gene mutations relate to outcomes and treatment responses in adults with advanced breast cancer.
-
Metronomic Oral Paclitaxel for Advanced HER2-Negative Breast Cancer
This study tests whether low, regular doses of an oral paclitaxel solution can be safely used to control tumor growth in adults with advanced HER2-negative breast cancer who have already had prior cancer therapy.
-
Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression
This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.